Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK2 | Q13002 | 3/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152230 | 0.90 | MTNR1A (0.53) | GRIK2GRIK1MTNR1AMTNR1BKDM4E | |
| SCHEMBL980098 | 0.86 | MMP3 (0.45) | GRIK2GRIK1MTNR1AMTNR1BLMNA | |
| SCHEMBL13152059 | 0.83 | GRIK2 (0.49) | GRIK2GRIK1LMNAKDM4EALDH1A1 | |
| SCHEMBL10252464 | 0.83 | GRIK2 (0.43) | GRIK2GRIK1KDM4EALDH1A1MAPK1 | |
| SCHEMBL13152383 | 0.83 | GRIK2 (0.45) | GRIK2GRIK1KDM4EALDH1A1MAPK1 | |
| SCHEMBL13152225 | 0.82 | ALDH1A1 (0.43) | GRIK2GRIK1MTNR1AKDM4EALDH1A1 | |
| SCHEMBL10249866 | 0.82 | GRIK2 (0.42) | GRIK2GRIK1MTNR1AMTNR1BLMNA | |
| SCHEMBL13152185 | 0.81 | GRIK2 (0.49) | GRIK2GRIK1KDM4EALDH1A1MAPK1 | |
| SCHEMBL13152064 | 0.81 | GRIK2 (0.49) | GRIK2GRIK1KDM4EALDH1A1MAPK1 | |
| SCHEMBL10097553 | 0.81 | MTNR1B (0.40) | MTNR1BMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | GRIK2 4399/4885GRIK1 4352/4885MTNR1A 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.